Clinical Trial Update: N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy [Phase 4]

View source ↗

Summary

This Phase 4 trial update examines N-GAL as a treatment for contrast-induced nephropathy in patients with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy
• Coronary Artery Disease

Drugs mentioned

• N-GAL

Snippet

Sponsor: University of Roma La Sapienza | Conditions: Coronary Artery Disease | Phase 4 | Status: UNKNOWN